Digest Network Come funziona
Network
/
Società
St
Non verificato

Stoke Therapeutics, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteScienza

52 comunicati stampa

Guarda tutti i comunicati
04/03/2026
Industria
Scienza
Igiene alimentare
Biotecnologia
Medicina - Varie
Salute
Farmaceutica
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
Fonte
Stoke Therapeutics, Inc.
Emittente
Business Wire
1.00
0
24/02/2026
Eventi
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
Fonte
Stoke Therapeutics, Inc.
Emittente
Business Wire
1.00
0
18/02/2026
Mercato azionario
Finanza
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Fonte
Stoke Therapeutics, Inc.
Emittente
Business Wire
1.00
0
11/02/2026
Scienza
Igiene alimentare
Biotecnologia
Medicina - Varie
Salute
Farmaceutica
Ottica
Industria
Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)
Fonte
Stoke Therapeutics, Inc.
Emittente
Business Wire
1.00
0
04/02/2026
Biotecnologia
Salute
Web e Social Network
Eventi
Fiere
Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Fonte
Stoke Therapeutics, Inc.
Emittente
Business Wire
1.00
0
16/01/2026
Salute
Biotecnologia
Scienza
Sanità
Farmaceutica
Mercato azionario
Finanza
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Fonte
Stoke Therapeutics, Inc.
Emittente
Business Wire
1.00
0
11/01/2026
Salute
Biotecnologia
Medicina - Varie
Scienza
Farmaceutica
Web e Social Network
Eventi
Industria
Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome
Fonte
Stoke Therapeutics, Inc.
Emittente
Business Wire
1.00
0
06/01/2026
Eventi
Web e Social Network
Salute
Biotecnologia
Medicina - Varie
Scienza
Farmaceutica
Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Fonte
Stoke Therapeutics, Inc.
Emittente
Business Wire
1.00
0
16/12/2025
Mercato azionario
Finanza
Scienza
Biotecnologia
Sanità
Salute
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Fonte
Stoke Therapeutics, Inc.
Emittente
Business Wire
1.00
0
05/12/2025
Scienza
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Eventi
Fiere
Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
Fonte
Stoke Therapeutics, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0